Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8097651 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(3 years from now) | |
US7759394 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8927604 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(3 years from now) | |
US9827197 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(3 years from now) |
Market Authorisation Date: 17 June, 2009
Treatment: Acute treatment of migraine attacks with or without aura in adults
Dosage: FOR SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8623920 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(6 years from now) | |
US7884095 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(6 years from now) | |
US9561200 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(6 years from now) | |
US8110606 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(6 years from now) | |
US7662858 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(6 years from now) | |
US7939518 | ASSERTIO | Method of treating post-surgical acute pain |
Feb, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | May 25, 2024 |
Market Authorisation Date: 16 June, 2009
Treatment: Diclofenac potassium for relief of mild to moderate acute pain; Nonsteroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain
Dosage: CAPSULE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic